RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재

      Bronchopulmonary Dysplasia and Ureaplasma: What Do We Know So Far?

      한글로보기

      https://www.riss.kr/link?id=A103567954

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Bronchopulmonary dysplasia (BPD) is the most common morbidity of prematurity. BPD is a chronic respiratory disease related to lung-injury during the primary course of critical lung disease such as respiratory distress syndrome or when abnormal develop...

      Bronchopulmonary dysplasia (BPD) is the most common morbidity of prematurity.
      BPD is a chronic respiratory disease related to lung-injury during the primary course of critical lung disease such as respiratory distress syndrome or when abnormal development of the preterm lung occurs. Abnormal lung development not only results from primary lung injury in the first days after birth, but also secondary injury through abnormal repair resulting in arrested and abnormal alveolarization, fibrosis and pulmonary vascular dysgenesis. Chorioamnionitis is a risk factor that plays an important role in the development of BPD. Ureaplasma subspecies (spp.) are the most common isolated organisms from chorioamniotic tissue after premature births. Therefore Ureaplasma spp. appear to play an important role in the development of BPD, and treatment or prophylactic treatment of these infections or colonization may reduce the incidence, morbidity and mortality of BPD. Ureaplasma spp. infections are challenging not only to treat, but also to diagnosis in a timely manner. This review summarizes the current state of treatment and new developments in the treatment of Ureaplasma exposure in premature infants.

      더보기

      참고문헌 (Reference)

      1 Ehrenkranz RA, "Validation of the National Institute of Health consensus definition of bronchopulmonary dysplasia" 116 : 1353-1360, 2005

      2 Ballard HO, "Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial" 46 : 111-118, 2011

      3 Li YH, "Ureaplasma urealyticum-induced production of proinflammatory cytokines by macrophages" 48 : 114-119, 2000

      4 Jonsson B, "Ureaplasma urealyticum, erythromycin and respiratory morbidity in high risk preterm neonates" 87 : 1079-1084, 1998

      5 Li YH, "Ureaplasma urealyticum induces apoptosis in human lung epithelial cells and macrophages" 82 : 166-173, 2002

      6 Kallapur SG, "Ureaplasma and BPD" 37 : 94-101, 2013

      7 Okogbule-Wonodi AC, "Surfactant protein-A enhances ureaplasmacidal activity in vitro" 17 : 145-151, 2011

      8 Viscardi RM, "Role of Ureaplasma respiratory tract colonization in bronchopulmonary dysplasia pathogenesis. Current concepts and update" 42 : 719-738, 2015

      9 Northway WH Jr., "Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia" 276 : 357-368, 1967

      10 Kotecha S, "Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants" 55 : 61-68, 2004

      1 Ehrenkranz RA, "Validation of the National Institute of Health consensus definition of bronchopulmonary dysplasia" 116 : 1353-1360, 2005

      2 Ballard HO, "Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial" 46 : 111-118, 2011

      3 Li YH, "Ureaplasma urealyticum-induced production of proinflammatory cytokines by macrophages" 48 : 114-119, 2000

      4 Jonsson B, "Ureaplasma urealyticum, erythromycin and respiratory morbidity in high risk preterm neonates" 87 : 1079-1084, 1998

      5 Li YH, "Ureaplasma urealyticum induces apoptosis in human lung epithelial cells and macrophages" 82 : 166-173, 2002

      6 Kallapur SG, "Ureaplasma and BPD" 37 : 94-101, 2013

      7 Okogbule-Wonodi AC, "Surfactant protein-A enhances ureaplasmacidal activity in vitro" 17 : 145-151, 2011

      8 Viscardi RM, "Role of Ureaplasma respiratory tract colonization in bronchopulmonary dysplasia pathogenesis. Current concepts and update" 42 : 719-738, 2015

      9 Northway WH Jr., "Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia" 276 : 357-368, 1967

      10 Kotecha S, "Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants" 55 : 61-68, 2004

      11 Hassan HE, "Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia" 51 : 1264-1275, 2011

      12 Merchan LM, "Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization" 59 : 570-578, 2015

      13 Olomu IN, "Perinatal correlates of Ureaplasma urealyticum in placenta parenchyma of singleton pregnancies that end before 28 weeks of gestation" 123 : 1329-1336, 2009

      14 Resch B, "Neonatal Ureaplasma urealyticum colonization increases pulmonary and cerebral morbidity despite treatment with macrolide antibiotics" 44 : 323-327, 2016

      15 Cultrera R, "Molecular evidence of Ureaplasma urealyticum and Ureaplasma parvum colonization in preterm infants during respiratory distress syndrome" 6 : 166-, 2006

      16 Miura Y, "Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection" 58 : 5413-5420, 2014

      17 Krausse R, "In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years" 16 : 1649-1655, 2010

      18 Furfaro LL, "In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin" 46 : 319-324, 2015

      19 Schmidt B, "Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely lowbirth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms" 289 : 1124-1129, 2003

      20 Kim SM, "Gastric fluid versus amniotic fluid analysis for the identification of intra-amniotic infection due to Ureaplasma species" 29 : 2579-2587, 2016

      21 Sung TJ, "Frequency of ureaplasma serovars in respiratory secretions of preterm infants at risk for bronchopulmonary dysplasia" 30 : 379-383, 2011

      22 Moss TJ, "Experimental amniotic fluid infection in sheep: effects of Ureaplasma parvum serovars 3 and 6 on preterm or term fetal sheep" 198 : 122-, 2008

      23 Mabanta CG, "Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum" CD003744-, 2003

      24 Garcia-Castillo M, "Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates" 62 : 1027-1030, 2008

      25 Schelonka RL, "Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques" 24 : 1033-1039, 2005

      26 Poindexter BB, "Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program" 12 : 1822-1830, 2015

      27 Ozdemir R, "Clarithromycin in preventing bronchopulmonary dysplasia in Ureaplasma urealyticum-positive preterm infants" 128 : e1496-e1501, 2011

      28 Katz B, "Characterization of ureaplasmas isolated from preterm infants with and without bronchopulmonary dysplasia" 43 : 4852-4854, 2005

      29 Hütten MC, "Can the preterm lung recover from perinatal stress?" 3 : 15-, 2016

      30 Nair V, "Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis" 106 : 337-347, 2014

      31 Wang EE, "Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity:results of a meta-analysis" 127 : 640-644, 1995

      32 Lowe J, "Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants. Updated systematic review and meta-analysis" 33 : 697-702, 2014

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2027 평가예정 재인증평가 신청대상 (재인증)
      2021-01-01 평가 등재학술지 유지 (재인증) KCI등재
      2018-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2015-01-01 평가 등재학술지 선정 (계속평가) KCI등재
      2013-07-31 학술지명변경 한글명 : 대한신생아학회지 -> Neonatal medicine
      외국어명 : Journal of the Korean Society of Neonatology -> Neonatal medicine
      KCI등재후보
      2013-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2012-01-01 평가 등재후보학술지 유지 (기타) KCI등재후보
      2011-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2009-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.15 0.15 0.26
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.23 0.2 0.563 0
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼